Clinical Trials on Essential Blepharospasm in Italy

Total 70 results

IRCCS San Raffaele
Servier

Completed

Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk

Hypertension,Essential

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Real World Evidence of Fedratinib Effectiveness in MF (REALFed)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Italy
University of Pavia

Unknown

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

Essential Hypertension

Italy
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Study MIPAE - Melatonin and Essential Arterial Hypertension (MIPAE)

Essential Hypertension

Italy
Federico II University
Agenzia Italiana del Farmaco

Completed

Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study (stayondiur)

Essential Hypertension

Italy
Ospedale San Raffaele

Recruiting

Genetic of Response to Acute Saline Load Test in Hypertension (Naload) (Naload)

Genetic Predisposition to Disease | Salt; Excess | Hypertension,Essential | Genetic Hypertension

Italy
Shire

Completed

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® (EMIX)

Essential Thrombocythemia (ET)

Italy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

The Confirmatory Olmesartan Plaque Regression Study (CONFIRM)

Essential Hypertension | Carotid Plaque

Italy
Emory University
Benign Essential Blepharospasm Research Foundation

Completed

Blepharospasm Tools

Dystonia | Blepharospasm | Other Eye and Face Disorders

United States, Canada, Italy, Germany
Ospedale San Raffaele

Completed

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant (ADD-AMI)

Genetic Hypertension | Hypertension Essential | Salt Excess

Italy
Federico II University

Completed

Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm | Prefibrotic/Early Primary Myelofibrosis

Italy
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia (ANAHYDRET)

Essential Thrombocythaemia

Austria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Singapore, Slovenia
Shire

Completed

Pediatric Disease Registry in Essential Thrombocythaemia (ET)

Essential Thrombocythemia (ET)

United Kingdom, Italy, Czechia, France, Germany, Greece, Spain, Switzerland
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
Incyte Corporation

Terminated

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Myeloproliferative Neoplasm (MPN)

United States, Italy
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
University of Pavia

Unknown

Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular

Diabetes Mellitus | Essential Hypertension

Italy
University of Pavia

Unknown

Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension

Essential Hypertension

Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Finland, Norway, Sweden, France, Germany, Italy, Turkey, Argentina, Chile, Ecuador, Spain, Switzerland
Bayer

Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Hypertension

Italy
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
University of Turin, Italy

Completed

Sympathetic Activity and Cardiometabolic Complications (SYMPACT)

Diabetes Mellitus, Type 2 | Metabolic Syndrome | Hypertension,Essential | Catecholamine; Overproduction | Hypertensive Heart Disease | Catecholamine; Secretion | Hypertensive Kidney Disease

Italy
RostaQuo S.p.A.

Unknown

Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

Essential Hypertension

Ireland, Italy, Poland
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy
Novartis Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

Hypertension

Czech Republic, Finland, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Sweden
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy, United Kingdom, France
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Familial Myeloproliferative Disorders

Polycythemia Vera | Essential Thrombocythemia | Idiopathic Myelofibrosis

United States, Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Essential Thrombocythemia

United States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Korea, Republic of, Malaysia, Italy, Germany, United Kingdom, Thailand, Poland, Turkey
Incyte Corporation

Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (LIMBER)

Anemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, France, Italy, Japan, United Kingdom, Canada
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Research Tissue Bank

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Idiopathic Myelofibrosis

United States, Italy
Boston Scientific Corporation

Recruiting

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

Essential Tremor

Germany, Korea, Republic of, Canada, Belgium, Hungary, Spain, Portugal, Italy
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Poland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
Menarini Group
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Hypertension

Poland, Germany, Israel, Romania, Italy, Denmark, Czechia, Croatia
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
Sankyo Pharma Gmbh

Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (OLMETREAT)

Essential Hypertension

France, Austria, Switzerland, Belgium, Germany, Italy, Netherlands, United Kingdom, Portugal
Incyte Corporation

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

Myelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...

United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
Novartis Pharmaceuticals

Completed

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension (ALLAY)

Hypertension | Overweight | Left Ventricular Hypertrophy

United States, Finland, Sweden, Germany, Italy, Spain, Argentina, Colombia, Russian Federation
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway

Clinical Trials on Essential Blepharospasm in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations